Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
..coulda woulda shoulda, run into the ground..too bad ...
FOXO EPIGENETICS AI LOW FLOATER IS THE KEYS TO AI
Data on the dark web no less, useless ...
Not great, but that's part of the game friend. Sometimes you lose.
..only $170M market cap, sell to highest bidder! ME$$,,,
AI, law enforcement/gov, pharma want ME dna database imo...
Corporate theft IMO. The CEO and her board of minions should be excluded from any voting on this.
Let insiders take private?, voting NO here...
How'd that work out?
Kathy Hibbs is selling about 35K shares per week but it should slow down since the price is now lower than what she gets them for. 42 cents
She only has like 115K left before they reload to feed themselves more shares
Didn't like it in the .60 and see even less to like at .44 -
I have only one question - Will it be a quick BK or a slow drawn out worthless attempt to infuse some sort of actual value?
Hey I'm a gambler but I'm not willing to put any money into this. The Q reads like a failing business venture to me. I saw absolutely no bright spots in the filing. It was worth a look to save my funds from devastating losses.
Buyside bias last 5 sessions. Will pop
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
ME
23andMe Holding Company
1.51
-0.015 (-0.98%)
Volume: 2,773,867
Day Range: 1.45 - 1.53
Last Trade Time: 7:59:42 PM EDT
23andMe Holding Co. NASDAQ: ME
GoSymbol lookup
Health Care : Health Care Providers & Services | Small Cap BlendCompany profile
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.
Great news today, anyone else excited by that green hammer at the close? Let's rock on Monday!
ME
23andMe Holding Company
1.67
0.04 (2.45%)
Volume: 1,009,450
Day Range: 1.64 - 1.71
Last Trade Time: 7:59:13 PM EDT
ME
23andMe Holding Company
1.64
0.05 (3.14%)
Volume: 7,698,993
Day Range: 1.57 - 1.65
Last Trade Time: 7:58:30 PM EDT
ME
23andMe Holding Company
2.07
0.03 (1.47%)
Volume: 4,213,342
Day Range: 1.8338 - 2.10
Last Trade Time: 7:59:16 PM EDT
ME
23andMe Holding Company
1.99
0.11 (5.85%)
Volume: 1,349,148
Day Range: 1.825 - 1.99
Last Trade Time: 7:36:16 PM EDT
Have 12k shares here now. The data here is extremely valuable.
ME
23andMe Holding Company
2.25
-0.04 (-1.75%)
Volume: 948,040
Day Range: 2.19 - 2.30
Last Trade Time: 7:56:39 PM EDT
ME
23andMe Holding Company
2.25
-0.04 (-1.75%)
Volume: 948,040
Day Range: 2.19 - 2.30
Last Trade Time: 7:56:39 PM EDT
ME
23andMe Holding Company
2.51
-0.08 (-3.09%)
Volume: 1,419,788
Day Range: 2.48 - 2.57
Last Trade Time: 7:24:32 PM EST
ME
23andMe Holding Company
2.59
-0.28 (-9.76%)
Volume: 3,437,659
Day Range: 2.49 - 2.68
Last Trade Time: 6:25:22 PM EST
ME
23andMe Holding Company
2.59
-0.28 (-9.76%)
Volume: 3,437,659
Day Range: 2.49 - 2.68
Last Trade Time: 6:25:22 PM EST
ME
23andMe Holding Company
2.68
-0.07 (-2.55%)
Volume: 2,344,468
Day Range: 2.64 - 2.80
Last Trade Time: 7:32:55 PM EST
ME
23andMe Holding Company
2.64
-0.05 (-1.86%)
Volume: 7,648,803
Day Range: 2.54 - 2.68
Last Trade Time: 7:58:03 PM EST
ME
23andMe Holding Company
2.8799
-0.0201 (-0.69%)
Volume: 2,373,575
Day Range: 2.78 - 2.92
Bid: 2.38
Ask: 3.37
Last Trade Time: 7:52:48 PM EDT
Total Trades: 12,726
ME Detailed Quote
Followers
|
19
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
170
|
Created
|
11/30/20
|
Type
|
Free
|
Moderators |
Most people know 23andMe (NASDAQ:ME) for its consumer-facing genetics testing kits,
and while this is certainly an excellent revenue stream, it's not the most exciting part of the company's business.
Where the real long-term potential lies is in the massive genetics data library the company has accumulated, with nearly 12 million genotyped individuals.
To put this in context, consider that the second-largest collection of genetic data belongs to Regeneron Pharmaceuticals, which has less than 10% of this amount.
Here's the point. 23andMe has a 50-50 partnership with pharmaceutical giant GlaxoSmithKline to leverage the company's genetics information to develop therapeutics.
The company currently has some exciting candidates, and if successful,
this could easily be a multibillion-dollar revenue stream for 23andme, which is currently valued at just $3.3 billion.
65 Bleecker Street
6th Floor
New York, NY 10012
FORM TYPE | RECEIVED | PERIOD END DATE | REPORT |
---|---|---|---|
4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
4 | 12/10/2020 | 12/08/2020 | PDFRTFHTMLXLS |
4/A | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
4 | 12/10/2020 | 09/24/2020 | PDFRTFHTMLXLS |
8-K | 11/20/2020 | 11/20/2020 | PDFRTFHTMLXLS |
10-Q | 11/16/2020 | 09/30/2020 | PDFRTFHTMLXLS |
8-K | 10/22/2020 | 10/16/2020 | PDFRTFHTMLXLS |
8-K | 10/13/2020 | 10/06/2020 | PDFRTFHTMLXLS |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |